NEW YORK — While Type-2 diabetes is expected to rise by more than a fifth, from 406 million in 2018 to 511 million in 2030 globally, India along with China and the U.S. will share over half of these high blood sugar cases, say researchers led by an Indian American, while asserting the need to improve access for the life saving insulin.
The study, published in The Lancet Diabetes and Endocrinology journal, showed that China (130 million) followed by India (98 million), and the U.S. (32 million) will constitute over half of Type-2 diabetics by 2030.
As a result, the amount of insulin needed to effectively treat Type-2 diabetes will rise by more than 20 per cent worldwide over the next 12 years.
Compared to current levels of insulin access, if universal global access was achieved (with a treatment target of HbA1c – measure of blood glucose) seven percent or lower, the number of people with Type-2 diabetes worldwide using insulin in 2030 would double from around 38 million (7.4 percent of all people with Type-2 diabetes) to 79 million (15.5 percent), the researchers said.
"Despite the UN's commitment to treat non-communicable diseases and ensure universal access to drugs for diabetes, across much of the world insulin is scarce and unnecessarily difficult for patients to access," said lead author Sanjay Basu from Stanford University.
"The number of adults with Type-2 diabetes is expected to rise over the next 12 years due to aging, urbanization, and associated changes in diet and physical activity.
"Unless governments begin initiatives to make insulin available and affordable, then its use is always going to be far from optimal," Basu said.